Therapeutic targeting of IL-7Rα signaling pathways in ALL treatment
Open accessThe DOI matches its Crossref record; 93 of the 94 references it cites were found in a registry or an index.
Abstract
Increased understanding of pediatric acute lymphoblastic leukemia (ALL) pathobiology has led to dramatic improvements in patient survival. However, there is still a need to develop targeted therapies to enable reduced chemotherapy intensity and to treat relapsed patients. The interleukin-7 receptor α (IL-7Rα) signaling pathways are prime therapeutic targets because these pathways harbor genetic aberrations in both T-cell ALL and B-cell precursor ALL. Therapeutic targeting of the IL-7Rα signaling pathways may lead to improved outcomes in a subset of patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“There is growing evidence indicating that excessive IL-7R signaling is oncogenic, being responsible for resistance to conventional chemotherapy and targeted therapeutics.38-40”
From PELI2 regulates early B-cell progenitor differentiation and related leukemia via the IL-7R expression (2023) · cites this paper as [38]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Lee, D. W., Kochenderfer, J. N., Stetler-Stevenson, M., Cui, Y. K., Delbrook, C., Feldman, S. A., Fry, T. J., Orentas, R., Sabatino, M., Shah, N. N., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(14)61403-3 · Cited by 2,898
Activating Mutations of NOTCH1 in Human T Cell Acute Lymphoblastic Leukemia
Weng, A. P., Ferrando, A. A., Lee, W., Morris, J. P., Silverman, L. B., Sanchez-Irizarry, C., Blacklow, S. C., Look, A. T., & Aster, J. C. (2004) · Science · doi:10.1126/science.1102160 · Cited by 2,715 · cited 1×
“50% of T-ALL cases.(18) NOTCH1 is the most commonly mutated gene in T-ALL and is known to regulate IL-7Ra transcription and expression.”
BackgroundThe genetic basis of early T-cell precursor acute lymphoblastic leukaemia
Zhang, J., Ding, L., Holmfeldt, L., Wu, G., Heatley, S. L., Payne-Turner, D., Easton, J., Chen, X., Wang, J., Rusch, M., et al. (2012) · Nature · doi:10.1038/nature10725 · Cited by 1,596 · cited 2×
“Activating mutations in JAK1 and JAK3 have been reported, and a TEL-JAK2 fusion has also been described.(17,20-26) Notably, JAK2 mutations generally seem to be more associated with B-cell precursor ALL (BCPALL) than T-ALL.”
BackgroundTreating Childhood Acute Lymphoblastic Leukemia without Cranial Irradiation
Pui, C.-H., Campana, D., Pei, D., Bowman, W. P., Sandlund, J. T., Kaste, S. C., Ribeiro, R. C., Rubnitz, J. E., Raimondi, S. C., Onciu, M., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0900386 · Cited by 1,215 · cited 1×
“90% in some series.(2) However, survival rates are much lower in children who experience relapse, varying between 21% and 39%.”
BackgroundA TEL-JAK2 Fusion Protein with Constitutive Kinase Activity in Human Leukemia
Lacronique, V., Boureux, A., Della Valle, V., Poirel, H., Quang, C. T., Mauchauffé, M., Berthou, C., Lessard, M., Berger, R., Ghysdael, J., et al. (1997) · Science · doi:10.1126/science.278.5341.1309 · Cited by 791
Development of PI3K inhibitors: lessons learned from early clinical trials
Rodon, J., Dienstmann, R., Serra, V., & Tabernero, J. (2013) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2013.10 · Cited by 766
Roberts, K. G., Morin, R. D., Zhang, J., Hirst, M., Zhao, Y., Su, X., Chen, S.-C., Payne-Turner, D., Churchman, M. L., Harvey, R. C., et al. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.06.005 · Cited by 714 · cited 9×
“New generations of JAK inhibitors are being developed to bind inactive forms of JAK to overcome resistance.64 Alternatively, JAK inhibitors may be combined with histone deacetylase (HDAC) inhibitors or heat shock protein 90 (HSP90) inhibitors.65,66 HDAC inhibitors induce hyperacetylation of HSP90, block its chaperone…”
BackgroundInfluentialLiu, Y.-J., Soumelis, V., Watanabe, N., Ito, T., Wang, Y.-H., de Waal Malefyt, R., Omori, M., Zhou, B., & Ziegler, S. F. (2007) · Annual Review of Immunology · doi:10.1146/annurev.immunol.25.022106.141718 · Cited by 659
Rearrangement of CRLF2 in B-progenitor– and Down syndrome–associated acute lymphoblastic leukemia
Mullighan, C. G., Collins-Underwood, J. R., Phillips, L. A. A., Loudin, M. G., Liu, W., Zhang, J., Ma, J., Coustan-Smith, E., Harvey, R. C., Willman, C. L., et al. (2009) · Nature Genetics · doi:10.1038/ng.469 · Cited by 623
Nguyen, K., Devidas, M., Cheng, S.-C., La, M., Raetz, E. A., Carroll, W. L., Winick, N. J., Hunger, S. P., Gaynon, P. S., Loh, M. L., et al. (2008) · Leukemia · doi:10.1038/leu.2008.251 · Cited by 582
Research works printed but not linked: 1
- Gutierrez, 2015, Acute lymphoblastic leukemia., 1527
Cited by
Flip the coin: IL-7 and IL-7R in health and disease
Barata, J. T., Durum, S. K., & Seddon, B. (2019) · Nature Immunology · doi:10.1038/s41590-019-0479-x · Cited by 375
Self-citationThe genetics and molecular biology of T-ALL
Girardi, T., Vicente, C., Cools, J., & De Keersmaecker, K. (2017) · Blood · doi:10.1182/blood-2016-10-706465 · Cited by 355
Winer, H. Y., Rodrigues, G. O. L., Hixon, J. A., Aiello, F. B., Hsu, T. C., Wachter, B. T., Li, W., & Durum, S. K. (2022) · Cytokine · doi:10.1016/j.cyto.2022.156049 · Cited by 142
Self-citationThe Role of IL-7 and IL-7R in Cancer Pathophysiology and Immunotherapy
Wang, C., Kong, L.-Z., Kim, S., Lee, S., Oh, S., Jo, S., Jang, I.-H., & Kim, T. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms231810412 · Cited by 146
“IL-7 mainly affects the proliferation and apoptosis of T-ALL cells by activating the JAK/STAT5 and PI3K/Akt/mTOR signaling pathways, leading to upregulation of transferrin receptor CD71, glucose transporter Glut1, glucose uptake and mitochondrial integrity [50,55,66,90,91].”
BackgroundLi, Y., Buijs-Gladdines, J. G. C. A. M., Canté-Barrett, K., Stubbs, A., Vroegindeweij, E. M., Smits, W. K., van Marion, R., Dinjens, W. N. M., Horstmann, M. A., Kuiper, R. P., et al. (2016) · PLoS Medicine · doi:10.1371/journal.pmed.1002200 · Cited by 118
Metadata
- Authors
- Cramer, S. D., Aplan, P. D., & Durum, S. K.
- Affiliations
- National Institutes of Health (US)
- Venue
- Blood
- Publisher
- American Society of Hematology
- Published
- 2016-07-28
- Volume
- 128
- Issue
- 4
- Pages
- 473-478
- ISSN
- 0006-4971 (ISSN-L)
- 1528-0020
- PMC
- PMC4965903
- OpenAlex
- W2418034645
- Cited by
- 43
- References
- 94
- Citations by year
- 2026: 3 · 2024: 2 · 2023: 2 · 2022: 2 · 2021: 8 · 2020: 5 · 2019: 6 · 2018: 9 · 2017: 4 · 2016: 2
- FWCI
- 1.05
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Blood (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Multiple Sclerosis Society
- Children's Cancer Foundation
- Multiple Sclerosis Society
- National Institutes of Health
- National Cancer Institute (Z01BC010931, ZIABC009287, ZIASC010378)
- Topics
- Health Sciences › Medicine › Hematology › Acute Lymphoblastic Leukemia research
- Health Sciences › Medicine › Oncology › CAR-T cell therapy research
- Health Sciences › Medicine › Hematology › Chronic Lymphocytic Leukemia Research
- Keywords
- IL-7 receptor alpha, IL-7 signaling, childhood acute lymphoblastic leukemia, targeted therapy, T-cell acute lymphoblastic leukemia, B-cell precursor acute lymphoblastic leukemia, relapsed leukemia, reduced-intensity chemotherapy, genetic alterations
- MeSH terms
- Humans, Neoplasm Proteins, Signal Transduction, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma, Interleukin-7, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Therapeutic targeting of IL-7Rα signaling pathways in ALL treatment. https://app.cochat.ai/papers/10.1182/blood-2016-03-679209
- The paper
- Cramer, S. D., Aplan, P. D., & Durum, S. K. (2016). Therapeutic targeting of IL-7Rα signaling pathways in ALL treatment. Blood. https://doi.org/10.1182/blood-2016-03-679209
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.